Fulcrum Therapeutics, Inc. has announced its financial results for the fourth quarter and full year of 2024, reporting a cash position of $241 million, providing a runway into at least 2027.

We came across a bullish thesis on Fulcrum Therapeutics, Inc. (FULC) on Stock Pursuit’s Substack. In this article, we will summarize the bulls’ thesis on FULC. Fulcrum Therapeutics, Inc. (FULC)'s ...

Wellington Management Group LLP reduced its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) by 2.3% in the 4th quarter, HoldingsChannel.com reports.

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks. Click to find out why FULC is a Hold.

Fulcrum Therapeutics, which trades on the Nasdaq Global Market under the ticker symbol FULC, is undergoing this realignment to better position itself for future growth and development within the ...